Becton, Dickinson and Company

BDX Healthcare Medical Instruments & Supplies

Becton, Dickinson and Company’s revenue for fiscal 2025 (year ended September 2025) was $21.8 billion, up 8.24% from fiscal 2024.

Revenue
−9.55%
EPS
−31.5%
Free cash flow
−31.6%
Total debt
−22.9%

Quarter to June 2026, against a year earlier

213.91 0.36 +0.17%
Market cap
$58.2B
P/E
64.1×
Fwd P/E
39.2×
Dividend yield
1.87%
F-score
7/9
Altman Z
1.85
Beneish M
−2.64
Dividend safety
67/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
45.58 39.81 25.34 25.65

+8 more quarters

P/S ratio
2.00 2.07 2.02 1.97
P/FCF ratio
12.98 12.63 16.86 16.14
P/Operating CF
53.59 65.76 67.51 23.27
P/B ratio
1.70 1.83 1.75 1.70
EV/Sales
2.60 2.71 2.75 2.74
EV/EBITDA
11.39 11.92 11.71 11.89
EV/FCF
16.93 16.54 22.90 22.44
Current Ratio
0.87 0.94 1.05 1.11
Net Debt/EBITDA
10.32 22.33 13.63 9.58
Debt/Equity
0.55 0.61 0.67 0.69
Earnings Yield
2.19% 2.51% 3.95% 3.90%
Free Cash Flow Yield
7.70% 7.92% 5.93% 6.20%
Free Cash Flow per Share
2.30 1.95 1.92 5.13
Book value per Share
88.85 85.99 88.53 88.27
Free Cash Flow
633.00 546.00 549.00 1,475.00
EV/EBIT
23.50 24.25 22.52 23.24
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026